DE69924254D1 - Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks - Google Patents

Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks

Info

Publication number
DE69924254D1
DE69924254D1 DE69924254T DE69924254T DE69924254D1 DE 69924254 D1 DE69924254 D1 DE 69924254D1 DE 69924254 T DE69924254 T DE 69924254T DE 69924254 T DE69924254 T DE 69924254T DE 69924254 D1 DE69924254 D1 DE 69924254D1
Authority
DE
Germany
Prior art keywords
reminder
medicament
manufacture
reducing eye
adenosine antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69924254T
Other languages
English (en)
Inventor
M Civan
A Stone
H Mitchell
Kenneth A Jacobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
University of Pennsylvania Penn
Original Assignee
National Institutes of Health NIH
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Health NIH, University of Pennsylvania Penn filed Critical National Institutes of Health NIH
Application granted granted Critical
Publication of DE69924254D1 publication Critical patent/DE69924254D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69924254T 1998-07-16 1999-07-15 Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks Expired - Lifetime DE69924254D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9309798P 1998-07-16 1998-07-16
US12296599P 1999-03-03 1999-03-03
PCT/US1999/016211 WO2000003741A2 (en) 1998-07-16 1999-07-15 Methods for reducing intraocular pressure using a3-adenosine antagonists

Publications (1)

Publication Number Publication Date
DE69924254D1 true DE69924254D1 (de) 2005-04-21

Family

ID=26787065

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69924254T Expired - Lifetime DE69924254D1 (de) 1998-07-16 1999-07-15 Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks

Country Status (8)

Country Link
US (2) US6528516B1 (de)
EP (1) EP1096975B1 (de)
JP (1) JP2003522729A (de)
AT (1) ATE290910T1 (de)
AU (1) AU765423B2 (de)
CA (1) CA2337499A1 (de)
DE (1) DE69924254D1 (de)
WO (1) WO2000003741A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
ID27600A (id) 1998-06-02 2001-04-12 Osi Pharm Inc KOMPOSISI PIROLO (2,3d) PIRIMIDIN DAN PENGGUNAANNYA
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
ES2172415B2 (es) 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
CA2437437A1 (en) * 2001-02-05 2002-08-15 Yasuhisa Kurogi Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, pharmaceutical, composition adenosine a3 receptor affinitive agent, intraocular-pressure reducing agent, pharmaceutical preparation for prevention and treatment of glaucoma, and intraocular-pressure reducing method
WO2003048120A2 (en) 2001-11-30 2003-06-12 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors
ES2528384T3 (es) 2001-12-12 2015-02-09 The Government Of The United States Of America, As Represented By The Secretary Department Of Healt Métodos de utilización de inhibidores del receptor de adenosina para potenciar la respuesta inmunitaria y la inflamación
US6916804B2 (en) 2001-12-20 2005-07-12 Osi Pharmaceuticals, Inc. Pyrimidine A2b selective antagonist compounds, their synthesis and use
US7084128B2 (en) * 2002-01-18 2006-08-01 Inspire Pharmaceuticals, Inc. Method for reducing intraocular pressure
AU2007307157A1 (en) * 2006-10-06 2008-04-17 The Trustees Of The University Of Pennsylvania Effective delivery of cross-species A3 adenosine-receptor antagonists to reduce intraocular pressure
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
WO2009123881A1 (en) * 2008-03-31 2009-10-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as a3 receptor- selective agonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
JP5431476B2 (ja) * 2008-08-01 2014-03-05 アメリカ合衆国 Ａ３アデノシン受容体アンタゴニストおよびａ３アデノシン受容体部分アゴニスト
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
SG10201502588UA (en) 2010-01-11 2015-05-28 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
JP2013523739A (ja) 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
US9227979B2 (en) 2012-01-25 2016-01-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fluorescent antagonists of the A3 adenosine receptor
SG11201403979TA (en) 2012-01-26 2014-08-28 Inotek Pharmaceuticals Corp Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof
EP2968389A4 (de) 2013-03-15 2016-08-24 Inotek Pharmaceuticals Corp Ophthalmische formulierungen
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
JP2019501949A (ja) 2016-01-14 2019-01-24 ハンドック インコーポレイテッド アデノシンａ３受容体拮抗化合物、その調製方法、およびその医学的使用
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0688973B2 (ja) * 1987-03-12 1994-11-09 京都薬品工業株式会社 １，４−ジヒドロピリジン誘導体
AU709190B2 (en) 1996-01-29 1999-08-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Dihydropyridine-, pyridine-, benzopyran- one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
US6528516B1 (en) 2003-03-04
WO2000003741A2 (en) 2000-01-27
EP1096975B1 (de) 2005-03-16
AU5109699A (en) 2000-02-07
AU765423B2 (en) 2003-09-18
US20030153626A1 (en) 2003-08-14
CA2337499A1 (en) 2000-01-27
EP1096975A2 (de) 2001-05-09
WO2000003741A3 (en) 2000-09-28
ATE290910T1 (de) 2005-04-15
JP2003522729A (ja) 2003-07-29

Similar Documents

Publication Publication Date Title
DE69924254D1 (de) Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks
EA200100678A1 (ru) N-уреидоалкил-пиперидины в качестве модуляторов активности рецепторов хемокинов
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
BR0310047A (pt) Análogos de 8-azaprostaglandina como agentes para diminuição de pressão intra-ocular
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
MX2007011300A (es) Solucion mejorada de bimatoprost oftalmico.
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
BRPI0418245B8 (pt) composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes
BR0116505A (pt) Compostos ou um sal deste farmaceuticamente aceitável, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios onde um antagonista de um receptor de orexina humano é requerido, e, processo para a fabricação de composições farmacêuticas para o tratamento de distúrbios associados com o papel da orexina, especialmente da obesidade e distúrbios do sono
NO960630D0 (no) Heterocykler anvendelige som neurokinin antagonister
BR0112582A (pt) Sulfonamidas de ciclilamina como agonistas de receptores beta-3 adrenérgicos
NO963731L (no) Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister
KR880012227A (ko) 도파민 수용체 길항제의 신규사용법
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
PT1129096E (pt) Antagonistas de receptor de crf e metodos de tratamento relacionados com os mesmos
MX344556B (es) Agonista de subtipo de receptor 5-ht1a.
BR0208405A (pt) Compostos de diidropirimina substituìdos com ciano e seu uso para tratar doenças
ZA202307013B (en) Salt form of isoquinolinone type compound as rock inhibitor and preparation method therefor
BR0307627A (pt) Métodos e composições para o tratamento de doenças do olho
PL360492A1 (en) Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates
WO2002102978A3 (en) Human growth hormone antagonists
ATE369856T1 (de) Verfahren zur behandlung von glaukom
BR0314419A (pt) Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
NO20053876D0 (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
BR0316775A (pt) Novos análogos de benzopirano e seu uso para o tratamento de glaucoma

Legal Events

Date Code Title Description
8332 No legal effect for de